James N Topper
CIK 1341382 · last filed 2026-05-21
James N Topper is a corporate insider who has filed 114 SEC Form 4 insider transactions across 17 companies since 2007. The most recent filing, for PHAT, was dated May 21, 2026. Across all open-market trades the lifetime net is +$281.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.11B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.11B
17
114
$281.48M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PHAT | Director | 126,121 | $11.66 | $1.47M | $100.19M | 10 | 2026-05-21 |
| NAMSW | Director | 3,801,000 | $19.38 | $73.66M | $586.2K | 8 | 2025-09-17 |
| MBX | 10%+ Owner | 4,552,774 | $60.06 | $273.44M | $40.00M | 1 | 2024-09-17 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 1,371,450 | $64.97 | $89.10M | $2.00M | 13 | 2024-05-20 |
| HilleVax, Inc. (HLVX) Delisted | 10%+ Owner | 8,544,187 | $2.09 | $17.86M | $641.6K | 1 | 2024-04-08 |
| ANAB | Director | 280,341 | $52.11 | $14.61M | $6.00M | 10 | 2023-01-10 |
| Allena Pharmaceuticals, Inc. (ALNA) Delisted | Director | 1,466,805 | $0.07 | $110.0K | $7.00M | 4 | 2020-11-18 |
| Aptinyx Inc. (APTX) Delisted | Director | 3,195,055 | $0.06 | $194.9K | $2.40M | 7 | 2020-04-02 |
| PASG | 10%+ Owner | 148,862 | $4.57 | $680.3K | $39.60M | 1 | 2020-03-03 |
| MIRM | 10%+ Owner | 3,116,912 | $112.23 | $349.81M | $27.00M | 1 | 2019-07-24 |
| Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Director | 337,707 | $2.19 | $739.6K | $5.64M | 2 | 2019-01-22 |
| Sierra Oncology, Inc. (SRRA) Delisted | Director | 148,148 | $54.99 | $8.15M | $8.00M | 1 | 2017-02-16 |
| Sierra Oncology, Inc. (DNAI) Delisted | Director | 1,966,195 | — | — | $3.74M | 2 | 2016-06-20 |
| GKOS | 10%+ Owner | 2,603,362 | $151.33 | $393.97M | $0 | 1 | 2015-06-30 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Director | 907,464 | $14.49 | $13.15M | $34.05M | 46 | 2013-06-17 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 7,252 | — | — | $0 | 2 | 2013-06-07 |
| LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Director | 84,214 | $6.22 | $523.8K | $4.63M | 4 | 2009-02-26 |
Recent Filings
114 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-21 | PHAT | Grant (A) | +24,122 | $0 | EDGAR |
| 2025-09-17 | NAMSW | Buy (P) | +660 | $15.6K | EDGAR |
| 2025-09-10 | NAMSW | Buy (P) | +1,260 | $31.5K | EDGAR |
| 2025-08-13 | NAMSW | Buy (P) | +471 | $11.3K | EDGAR |
| 2025-06-26 | NAMSW | Buy (P) | +3,780 | $69.5K | EDGAR |
| 2025-06-18 | NAMSW | Buy (P) | +8,584 | $167.4K | EDGAR |
| 2025-06-05 | PHAT | Grant (A) | +10,500 | $0 | EDGAR |
| 2025-05-23 | PHAT | Buy (P) | +3,780 | $14.6K | EDGAR |
| 2025-05-15 | PHAT | Buy (P) | +7,420 | $24.5K | EDGAR |
| 2025-05-13 | PHAT | Buy (P) | +48,203 | $152.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.